Yasushi Yoshimura - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Yasushi Yoshimura

Showing results (31-40 of 33) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 33 results.

Nature Communications|January 5, 2020

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulationTakahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, et al.

Molecular Cancer Research : MCR|September 2, 2018

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance ModelTakahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, et al.

Bioorganic & Medicinal Chemistry Letters|February 15, 2011

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agentYoshiaki Isshiki, Yasunori Kohchi, Hitoshi Iikura, et al.

Pageof 4

Search research articles

Showing results (31-40 of 33) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 33 results.

Nature Communications|January 5, 2020

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulationTakahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, et al.

Molecular Cancer Research : MCR|September 2, 2018

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance ModelTakahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, et al.

Bioorganic & Medicinal Chemistry Letters|February 15, 2011

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agentYoshiaki Isshiki, Yasunori Kohchi, Hitoshi Iikura, et al.

Pageof 4